Title:
ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/139919
Kind Code:
A1
Abstract:
Disclosed herein are acetal and cyclic acetal compounds, compositions, their preparation, and their uses. Some embodiments relate to their use as liver-targeting compounds.
More Like This:
Inventors:
ZHI LIN (US)
Application Number:
PCT/US2019/012762
Publication Date:
July 18, 2019
Filing Date:
January 08, 2019
Export Citation:
Assignee:
LIGAND PHARM INC (US)
International Classes:
C07D405/06; A61K31/506; A61P1/16; A61P3/06; A61P3/10; C07D239/42; C07D405/14
Domestic Patent References:
| WO2017137469A1 | 2017-08-17 | |||
| WO2007125547A2 | 2007-11-08 | |||
| WO2010103320A1 | 2010-09-16 | |||
| WO2012038785A1 | 2012-03-29 | |||
| WO1987005297A1 | 1987-09-11 |
Foreign References:
| US8354530B2 | 2013-01-15 | |||
| CN102079726A | 2011-06-01 | |||
| KR20170078033A | 2017-07-07 | |||
| CN107382875A | 2017-11-24 | |||
| US20170183314A1 | 2017-06-29 | |||
| US8207333B2 | 2012-06-26 | |||
| KR20160126700A | 2016-11-02 | |||
| KR20100087931A | 2010-08-06 |
Other References:
AHMAD, S. ET AL.: "3R,5S,E)-7-(4-(4-Fluorophenyl)-6-isopropyl-2-(methyl(1-methyl- 1H-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS- 644950): A rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitor with reduced myotoxicity potential", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, 2008, pages 2722 - 2733, XP055003825, doi:10.1021/jm800001n
LEE, Y. H. ET AL.: "Synthesis and characterization of rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor", TETRAHEDRON LETTERS, vol. 58, no. 26, 28 February 2017 (2017-02-28), pages 2614 - 2617, XP055625067
"Goodman and Gilman's: The Pharmacological Basis of Therapeutics", 1990, PERGAMON PRESS
"Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
P.G.M. GREENT.W. WUTTS: "Protecting Groups in Organic Synthesis", 1999, WILEY
LIEBERMAN ET AL., PHARMACEUTICAL DOSAGE FORMS: TABLETS, 1989
"Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS
"Remington's The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Modern Pharmaceutics", 2002
ANSEL: "Introduction to Pharmaceutical Dosage Forms", 2004
POWELL ET AL.: "Compendium of Excipients for Parenteral Formulations", PDA J PHARM SCI AND TECH, vol. 52, 1998, pages 238 - 311, XP009119027
NEMA ET AL.: "Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions", PDA J PHARM SCI AND TECH, vol. 65, 2011, pages 287 - 332, XP009166667, DOI: 10.5731/pdajpst.2011.00634
See also references of EP 3737676A4
LEE, Y. H. ET AL.: "Synthesis and characterization of rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor", TETRAHEDRON LETTERS, vol. 58, no. 26, 28 February 2017 (2017-02-28), pages 2614 - 2617, XP055625067
"Goodman and Gilman's: The Pharmacological Basis of Therapeutics", 1990, PERGAMON PRESS
"Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
P.G.M. GREENT.W. WUTTS: "Protecting Groups in Organic Synthesis", 1999, WILEY
LIEBERMAN ET AL., PHARMACEUTICAL DOSAGE FORMS: TABLETS, 1989
"Encyclopedia of Reagents for Organic Synthesis", 1995, JOHN WILEY AND SONS
"Remington's The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"Modern Pharmaceutics", 2002
ANSEL: "Introduction to Pharmaceutical Dosage Forms", 2004
POWELL ET AL.: "Compendium of Excipients for Parenteral Formulations", PDA J PHARM SCI AND TECH, vol. 52, 1998, pages 238 - 311, XP009119027
NEMA ET AL.: "Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions", PDA J PHARM SCI AND TECH, vol. 65, 2011, pages 287 - 332, XP009166667, DOI: 10.5731/pdajpst.2011.00634
See also references of EP 3737676A4
Attorney, Agent or Firm:
ALTMAN, Daniel E. (US)
Download PDF: